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resistance. All over the world, asking for new anticancer agents is still a major goal for medicinal 
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INTRODUCTION 
Cancer is one of the most striking diseases that has a potential 
impact on human health with high mortality rate [1,2]. During 
the last century many anticancer agents have emerged but 
unfortunately, these agents could not provide effective 
solutions for cancer treatment due to side effects and resistance 
[1,3] . Therefore, asking for new anticancer agents is still a 
major goal for medicinal chemists all over the world. Among 
many chemical scaffolds with anticancer activity, pyrrole and 
pyrimidine derivatives I-VI comprise a major class of several 
trials to develop new anticancer agents Fig 1. Their anticancer 
activity was achieved through inhibition of several enzymes [4-
9]. Different novel pyrrole derivatives bearing sulfonamide 
moiety were reported to have promising activity against human 
liver cancer cell line (HepG2) and human breast cancer cell line 
(MCF-7) [10] through protein kinases inhibition [11]. Through 
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the past few years, designing novel VEGFR-2 inhibitors have 
received great attention [12]. Among anti angiogenesis agents, 
VEGFR-2 inhibitors were used to control growth of tumors 
[13]. VEGFRs comprise a type of receptor tyrosine kinases 
(RTKs) which consist of single transmembrane domain that 
separates extracellular domain from intracellular tyrosine 
kinase region [14-18].Based on fore-mentioned facts and as a 
trial to design and synthesize  new anticancer agents with 
VEGFR-2 inhibitory activity, new substituted 5,7-diphenyl 
pyrrole and pyrrolo[2,3-d]pyrimidine derivatives were 
synthesized bearing carboxylic moiety as bioisostere to 
sulfonamide moiety in order to explore their cytotoxic activity 
as VEGFR-2inhibiting action.  
 
This rationale was based on the virtual activity of some 5,7-
diphenyl pyrrolo[2,3-d]pyrimidine derivative with sulfonamide 
group rather than our bioiososteric carboxylic group [14]. 
Moreover, some amide derivatives with sulfonamide moiety 
were synthesized for comparing their antitumor activity with 
their carboxylic analogues. The cytotoxic activity against 
human liver cancer cell line HepG2 and human breast cancer 
cell line MCF-7 of all synthesized compounds were evaluated 
using doxorubicin and as reference standard. The inhibitory 
activity of most active four compounds against vascular 
endothelial growth factor receptor-2 (VEGFR-2) was 
evaluated. 
 
MATERIALS & METHODS 
2.1. Experimental 
Melting points were determined on Electrothermal Stuart 
SMP3 digital melting point apparatus and were uncorrected. 
Elemental microanalyses were performed at the Regional 
Center for Mycology and Biotechnology, Al-Azhar University. 
Infrared spectra were determined (KBr) using Shimadzu 
Infrared spectrometer (IR-435) and FT-IR 1650 (Perkin Elmer), 
Faculty of Pharmacy, Cairo University. 
1
H-NMR spectra were 
performed in DMSO-d6 using Joel, 300 MHz NMR 
spectrometer, Faculty of Science, Cairo University and Bruker, 
400 MHz NMR spectrometer, Microanalytical unit, Faculty of 
Pharmacy, Cairo University. 
13
C-NMR spectra were recorded 
using Bruker, 100 MHz NMR spectrometer, Microanalytical 
unit, Faculty of Pharmacy, Cairo University. Mass spectra were 
performed at the Regional Center for Mycology and 
Biotechnology, Al-Azhar University. Thin layer 
chromatography was carried out on silica gel TLC plates with 
fluorescence indicator (F254).       
                                     
2.1.1. 4-((2-Oxo-2-phenylethyl)amino)benzoic  acid 1                                            
A mixture of p-amino benzoic acid (1.37 g, 0.01 mol) and 
phenacyl bromide (1.98 g, 0.01 mol) in absolute ethanol (10 
ml) refluxed for 3 hours. The yielded solid was filtered, dried 
and crystallized from dioxane to give 1. Yellow powder, yield 
51%, melting point 220 °C (190°C reported [19])   IR: νmax./cm
-
1
 3356.14 (NH), 3051.39 (CH arom.), 2972.31 (CH aliph.), 
2546.04 (OH), 1675, 1670.35 (2 C=O). 
1
H NMR (DMSO-d6) δ: 
4.78 (s, 2H, CH2), 6.69 (m, 3H, Ar-H + NH, D2O 
exchangeable), 7.54-7.71 (m, 5H, Ar-H), 8.06 (d, 2H, Ar-H, J= 
8.1 Hz), 12.10 (s, 1H, OH, D2O exchangeable). 
13
C NMR 
(DMSO-d6) δ: 50.0, 112.0 (2), 117.3, 128.4 (2), 128.8 (2), 
131.3 (2), 134.1, 135.4, 152.5, 167.7 (COOH), 196.5 (C=O). 
Anal. Calculated. for C15H13NO3 (255.27): C, 70.58;  H, 5.13;  
N, 5.49. Found: C, 70.69; H, 5.17; N, 5.72. Ms (m/z, %): 255 
(M
+
, 8.11) 
                         
2.1.2.4-(2-Amino-3-cyano-4-phenyl-1H-pyrrol-1-yl)benzoic 
acid 2              
A mixture of 1 (2.55 g, 0.01 mol) and malononitrile (0.66 g, 
0.01 mol) in absolute ethanol (30 ml) / sodium hydroxide (0.5 
gm)  refluxed for 12 hours. The reaction mixture cooled, 
poured on ice/water and acidified with dil. acetic acid. The 
obtained solid was crystallized from dioxane to give 2. Orange 
brown powder, yield 89%, melting point 250 °C, IR:  νmax./cm
-1 
3402.43, 3338.78 (NH2), 3057.17 (CH arom.), 2540 (OH), 
2200.78 (CN), 1685.79 (C=O). 
1
H NMR (DMSO-d6) δ: 6.09 (s, 
2H, NH2, D2O exchangeable), 6.96 (s, 1H, CH pyrrole), 7.23 
(d, 2H, Ar-H, J= 8.9 Hz), 7.27-7.66 (m, 5H, Ar-H), 8.06 (d, 
2H, Ar-H, J= 8.7 Hz), 13.00 (s, 1H, OH, D2O exchangeable). 
13
C NMR (DMSO-d6) δ: 71.3, 113.4 (C≡N), 118.3, 123.2, 
125.1, 125.9 (2), 127.1, 129.7 (2), 130.7 (2), 131.2 (2), 133.5, 
140.9, 148.7, 167.3 (COOH). Anal. Calcd. for C18H13N3O2 
(303.31): C, 71.28;  H, 4.32; N, 13.85. Found: C, 71.43; H, 
4.30; N, 14.03. Ms (m/z, %): 303 (M
+
, 100).    
 
2.1.3 4-(4-Amino-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl) 
benzoic acid 3 
A solution of 2 (3.03 g, 0.01 mol.) withformamide (30 ml) was 
refluxed for   10 hours. The reaction mixture was cooled, 
poured on ice/water and the solid obtained was crystallized 
from dioxane to give 3. Black powder, yield 98%, melting 
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point 240 °C, IR:  νmax./cm
-1
 3304.06, 3167.12 (NH2), 3061.03 
(CH arom.), 2879.72 (OH), 1678.07 (C=O). 
1
H NMR (DMSO-
d6) δ: 6.23 (s, 2H, NH2, D2O exchangeable), 7.38 (d, 2H, Ar-H, 
J= 9.0 Hz), 7.41-7.95 (m, 6H, Ar-H + CH pyrrole), 8.02 (d, 2H, 
Ar-H, J= 8.7 Hz), 8.26 (s, 1H, CH pyrimidine). 
13
C NMR 
(DMSO-d6) δ: 101.7, 118.2, 123.0, 127.7, 129.1 (2), 129.5, 
130.8, 132.1 (2), 134.4 (2), 140.3 (2), 150.8, 153.0, 158.1, 
163.4, 167.6 (COOH). Anal. Calcd. for C19H14N4O2 (330.34): 
C, 69.08;  H, 4.27; N, 16.96. Found: C, 69.24; H, 4.34; N, 
17.15           
                                                                   
2.1.4 4-(4-Oxo-5-phenyl-3,4-dihydro-7H-pyrrolo[2,3-d] 
pyrimidin-7-yl) benzoic acid 4 
A solution of 2 (3.03 g, 0.01 mol.) with formic acid (30 ml) 
was refluxed for 10 hours. The reaction mixture was cooled, 
poured on ice/water and the yielded solid was crystallized from 
ethanol to give 4. Brown powder, yield 97%, melting point 
>300 °C, IR:  νmax./cm
-1
 3149.76 (NH), 3053.32 (CH arom.), 
2550 (OH), 1685.79, 1654.92 (2 C=O). 
1
H NMR (DMSO-d6) δ: 
7.24 (d, 2H, Ar-H, J= 8.9 Hz), 7.39-8.06 (m, 7H, Ar-H + CH 
pyrrole and CH pyrimidine), 8.09 (d, 2H, Ar-H, J= 8.9 Hz), 
12.22 (s, 1H, NH, D2O exchangeable), 12.96 (s, 1H, OH, D2O 
exchangeable). 
13
C NMR (DMSO-d6) δ: 107.0, 121.7, 121.9, 
124.5, 126.9 (2), 128.8, 128.5 (2), 130.7 (2), 133.6 (2), 141.1, 
145.2, 148.6, 158.8, 163.5 (C=O), 167.2 (COOH).                                                                                                    
Anal. Calcd. for C19H13N3O3 (331.32): C, 68.88;  H, 3.95; N, 
12.68.  Found: C, 68.97; H, 4.07; N, 12.57. Ms (m/z, %): 331 
(M
+
, 100).     
 
2.1.5.  4-(4-Amino-2-oxo-5-phenyl-1,2-dihydro-7H-
pyrrolo[2,3-d]pyrimidin-7-yl)benzoic acid 5 
A mixture of 2 (3.03 g, 0.01 mol.) and urea (0.6 g, 0.01 mol) 
fused at 220°C for 15 minutes on sand bath. The solid obtained 
was triturated with ethanol then filtered and crystallized from 
methanol to give 5. Yellowish brown powder, yield 85%, 
melting point 210 °C, IR:  νmax./cm
-1
 3462.22, 3348.42, 3207.62 
(NH, NH2), 3062.96 (CH arom.), 2750 (OH), 1716.65, 1697.36 
(2 C=O). 
1
H NMR (DMSO-d6) δ: 5.37 (s, 2H, NH2, D2O 
exchangeable), 7.39-7.98 (m, 10H, Ar-H + CH pyrrole), 8.04 
(s, 1H, NH, D2O exchangeable), 11.00 (s, 1H, OH, D2O 
exchangeable). 
13
C NMR (DMSO-d6) δ: 112.9, 117.0, 118.1, 
119.1, 120.5 (2), 121.5, 122.8 (2), 128.4 (2), 129.0 (2), 130.5, 
131.6, 150.4, 155.9 (C=O), 160.1, 167.6 (COOH). Anal. Calcd. 
for C19H14N4O3 (346.34): C, 65.89;  H, 4.07; N, 16.18.              
Found: C, 66.03; H, 4.03; N, 16.39.     
2.1.6. Synthesis of compounds 6 and 7 
A solution of 2 (3.03 g, 0.01 mol.) in acetic anhydride (30 ml) 
was refluxed for 15 minutes resulting in compound 6 and for 3 
hours resulting in compound 7. The reaction mixture was 
cooled, poured on ice/water while stirring and the yielded solid 
was crystallized from ethanol.                         
 
2.1.6.1.4-(2-Acetamido-3-cyano-4-phenyl-1H-pyrrol-1-yl) 
benzoic acid 6     
Brownish yellow powder, yield 75%, melting point 130 °C, IR:  
νmax./cm
-1
 3223.05 (NH), 3062.96-3014.74 (CH arom.), 
2536.39 (OH), 2223.92 (CN), 1695.43 (2 C=O). 
1
H NMR 
(DMSO-d6) δ: 1.97 (s, 3H, CH3), 7.34-8.10 (m, 10H, Ar-H + 
CH pyrrole), 10.17 (s, 1H, NH, D2O exchangeable), 13.00 (s, 
1H, OH, D2O exchangeable). 
13
C NMR (DMSO-d6) δ: 25.8 
(CH3), 90.0, 115.8 (C≡N), 119.0, 121.2, 124.5, 124.9 (2), 
126.4, 127.8 (2), 129.5 (2), 131.0 (2), 132.5, 134.5, 140.8, 
167.0 (COOH), 170.7 (C=O). Anal. Calcd. for C20H15N3O3 
(345.35): C, 69.56;  H, 4.38; N, 12.17. Found: C, 69.74; H, 
4.40; N, 12.40.                                                          
 
2.1.6.2.4-(2-(N-acetylacetamido)-3-cyano-4-phenyl-1H-pyrrol-
1-yl) benzoic acid 7  
Brown powder, yield 60%, melting point 140 °C, IR:  νmax./cm
-1
 
2225.85 (CN), 1811.16, 1745.58, 1705.07 (3 C=O). 
1
H NMR 
(DMSO-d6) δ: 1.90 (s, 3H, CH3), 2.25 (s, 3H, CH3), 7.47-7.77 
(m, 5H, Ar-H), 7.37 (d, 2H, Ar-H, J= 9.0 Hz), 7.90 (s, 1H, CH 
pyrrole), 8.09 (d, 2H, Ar-H, J= 8.9 Hz), 12.80 (s, 1H, OH, D2O 
exchangeable). 
13
C NMR (DMSO-d6) δ: 25.7 (2CH3), 91.8, 
114.8 (C≡N), 119.0, 121.2, 125.7, 126.4 (2), 128.3, 129.5 (2), 
131.5 (2), 131.9 (2), 133.8, 134.5, 139.6, 166.7 (COOH), 172.4 
(2C=O). Anal. Calcd. for C22H17N3O4 (387.39): C, 68.21;  H, 
4.42; N, 10.85. Found: C, 68.33; H, 4.49; N, 10.97. Ms (m/z, 
%): 387 (M
+
, 12.96).    
          
2.1.7. 4-(3-Cyano-4-phenyl-2-ureido-1H-pyrrol-1-yl)benzoic 
acid 8                       
A mixture of 2 (3.03 g, 0.01 mol.) with urea (0.6 g, 0.01 mol) 
in absolute ethanol (30 ml) / sodium hydroxide (0.5 g) was 
refluxed for 12 hours. The reaction mixture was cooled, poured 
on ice/water and acidified with diluted acetic acid. The solid 
obtained was crystallized from dioxane to give 8. Brown 
powder, yield 70%, melting point 233 °C, IR:  νmax./cm
-1
 
3402.43, 3336.85, 3317.56 (NH, NH2), 3061.03 (CH arom.), 
2522.89 (OH), 2200.78 (CN), 1689.64 (2 C=O). 
1
H NMR 
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(DMSO-d6) δ: 6.01 (s, 2H, NH2, D2O exchangeable), 6.95 (s, 
1H, CH pyrrole), 7.23 (d, 2H, Ar-H, J= 6.0 Hz), 7.28-7.66 (m, 
6H, Ar-H + NH, D2O exchangeable), 8.06 (d, 2H, Ar-H, J= 6.0 
Hz). 
13
C NMR (DMSO-d6) δ: 78.25, 112.0 (C≡N), 118.0, 
122.9, 125.5, 126.5 (2), 127.8, 129.3 (2), 129.9 (2), 131.6 (2), 
132.8, 141.3, 153.8, 162.8 (C=O), 167.1 (COOH). Anal. Calcd. 
for C19H14N4O3 (346.34): C, 65.89;  H, 4.07; N, 16.18.                   
Found: C, 66.04; H, 4.13; N, 16.34.  
 
2.1.8. Synthesis of compounds 9-13 
A mixture of 2 (3.03 g, 0.01 mol.) and the corresponding 
aromatic aldehyde (0.01 mol) in absolute ethanol (30 ml) was 
refluxed for 6 hours,concentrated and cooled. The yielded solid 
was crystallized from ethanol to give 9-13, respectively.                                                                                            
2.1.8.1. 4-(2-(Benzylideneamino)-3-cyano-4-phenyl-1H-pyrrol-
1-yl)benzoicacid9Yellow powder, yield 55%, melting point 
263 °C, IR:  νmax./cm
-1
 3032.10 (CH arom.), 2665.62 (OH), 
2214.28 (CN), 1691.57 (C=O). 
1
H NMR (DMSO-d6) δ: 7.37 (d, 
2H, Ar-H, J= 6.0 Hz), 7.48-7.89 (m, 11H, Ar-H + CH pyrrole), 
8.08 (d, 2H, Ar-H, J= 6.0 Hz), 9.14 (s, 1H, HC=N), 13.08 (s, 
1H, OH, D2O exchangeable). 
13
C NMR (DMSO-d6) δ: 79.6, 
117.5 (C≡N), 119.8, 125.8, 126.0, 126.7 (2), 128.0, 129.5 (2), 
129.6 (2), 130.3 (2), 130.6 (2), 132.6 (2), 133.5, 135.5 (2), 
141.0, 147.0, 163.6 (C=N), 167.0 (COOH). Anal. Calcd. for 
C25H17N3O2 (391.42): C, 76.71;  H, 4.38; N, 10.74.                           
Found: C, 76.87; H, 4.44; N, 10.88.                                                                         
 
2.1.8.2.   4-(2-((4-Chlorobenzylidene)amino)-3-cyano-4-
phenyl-1H-pyrrol-1-yl)benzoic acid 10 
Yellow powder, yield 60%, melting point >300 °C, IR:  
νmax./cm
-1
 3030.17 (CH arom.), 2550 (OH), 2231.64 (CN), 
1724.36 (C=O). 
1
H NMR (DMSO-d6) δ: 6.99 (s, 1H, CH 
pyrrole), 7.36 (d, 2H, Ar-H, J= 8.9 Hz), 7.46-7.89 (m, 9H, Ar-
H), 8.07 (d, 2H, Ar-H, J= 8.9 Hz), 9.14 (s, 1H, HC=N), 13.05 
(s, 1H, OH, D2O exchangeable). 
13
C NMR (DMSO-d6) δ: 79.8, 
117.4 (C≡N), 120.0, 125.2, 125.9, 126.6 (2), 127.0 (2), 128.0, 
129.4 (2), 130.0 (2), 130.6 (2), 131.1 (2), 131.2, 132.5, 134.4, 
137.8, 146.5, 161.9 (C=N), 167.0 (COOH). Anal. Calcd. for 
C25H16ClN3O2 (425.87): C, 70.51;  H, 3.79; N, 9.87.                 
Found: C, 70.62; H, 3.84; N, 9.96. 
 
2.1.8.3. 4-(3-Cyano-2-((4-methoxybenzylidene) amino)-4-
phenyl-1H-pyrrol-1-yl)benzoic acid 11                                                                                                  
Orange powder, yield 60%, melting point 285 °C, IR:  νmax./cm
-
1
 3014.74 (CH arom.), 2924.09 (CH aliph.), 2540 (OH), 
2202.71 (CN), 1691.57 (C=O). 
1
H NMR (DMSO-d6) δ: 3.85 (s, 
3H, CH3), 7.08 (d, 2H, Ar-H, J= 8.7 Hz), 7.10-7.85 (m, 10H, 
Ar-H + CH pyrrole), 8.06 (d, 2H, Ar-H, J= 8.4 Hz), 9.04 (s, 
1H, HC=N), 13.07 (s, 1H, OH, D2O exchangeable). 
13
C NMR 
(DMSO-d6) δ: 56.0 (CH3), 79.0, 115.1 (C≡N), 117.7 (2), 119.2, 
125.8, 126.6, 127.9 (2), 128.3, 129.5 (2), 130.1, 130.5 (2), 
131.6(2), 132.6 (2), 141.1 (2), 147.5, 162.9 (C=N), 163.6, 
167.0 (COOH). Anal. Calcd. for C26H19N3O3 (421.45): C, 
74.10; H, 4.54; N, 9.97. Found: C, 74.22; H, 4.59; N, 10.09. Ms 
(m/z, %): 421 (M
+
, 100).                         
 
2.1.8.4. 4-(3-Cyano-2-((4-(dimethylamino) benzylidene) 
amino)-4-phenyl-1H-pyrrol-1-yl)benzoic acid 12            
Orange powder, yield 60%, melting point 278 °C, IR:  νmax./cm
-
1
 3055.24 (CH arom.), 2550 (OH), 2214.28 (CN), 1712.79 
(C=O). 
1
H NMR (DMSO-d6) δ: 3.03 (s, 6H, 2 CH3), 6.77 (d, 
2H, Ar-H, J= 9.0 Hz), 7.31-7.79 (m, 10H, Ar-H + CH pyrrole), 
8.05 (d, 2H, Ar-H, J= 8.4 Hz), 8.88 (s, 1H, HC=N), 13.16 (s, 
1H, OH, D2O exchangeable). 
13
C NMR (DMSO-d6) δ: 56.0 
(2CH3), 71.4, 111.5 (C≡N), 113.5 (2), 116.2, 118.2, 119.0, 
123.1, 125.4 (2), 125.9 (2), 126.5, 127.1 (2), 127.9 (2), 129.4 
(2), 130.0, 131.2, 141.1, 148.6, 163.0 (C=N), 167.0 (COOH). 
Anal. Calcd. for C27H22N4O2 (434.49): C, 74.64;  H, 5.10; N, 
12.89. Found: C, 74.72; H, 5.14; N, 13.12. 
2.1.8.5. 4-(3-Cyano-2-((4-hydroxy-3-methoxybenzylidene) 
amino)-4-phenyl-1H-pyrrol-1-yl)benzoic acid 13     
Yellowish  orange powder, yield 65%, melting point 168 °C, 
IR:  νmax./cm
-1
 3421.72 (OH phenolic), 3034.03 (CH arom.), 
2540 (OH carboxylic), 2208.49 (CN), 1691.57 (C=O). 
1
H 
NMR (DMSO-d6) δ: 3.84 (s, 3H, CH3), 6.91-8.06 (m, 9H, Ar-H 
+ CH pyrrole), 7.25 (d, 2H, Ar-H, J= 9.0 Hz), 8.06 (d, 2H, Ar-
H, J= 8.9 Hz), 8.96 (s, 1H, HC=N), 10.05 (s, 1H, OH phenolic, 
D2O exchangeable), 13.03 (s, 1H, OH carboxylic, D2O 
exchangeable). 
13
C NMR (DMSO-d6) δ: 56.0 (CH3), 71.4, 
113.0 (C≡N), 113.5, 118.2 (2), 121.8, 123.1, 125.2 (2), 125.9, 
127.0 (2), 129.0 (2), 130.4 (2), 131.0 (2), 131.6 (2), 133.6, 
141.0, 148.8, 167.2 (C=N), 167.5 (COOH). Anal. Calcd. for 
C26H19N3O4 (437.45): C, 71.39;  H, 4.38; N, 9.61. Found: C, 
71.54; H, 4.42; N, 9.75. 
 
2.1.9. Synthesis of compounds 14 and 15                                                                    
A mixture of compound 2 (3.03 g, 0.01 mol.) with thionyl 
chloride was refluxed for 3 hours, the excess thionyl chloride 
was distilled out till dryness under reduced pressure. The 
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residue was refluxed with the corresponding sulfonamide (0.01 
mol.) and 4 drops of pyridine in dry benzene (30 ml) for 6-8 
hours. The reaction mixture was concentrated and cooled.The 
yielded solid was crystallized from methanol to give 14 and 15. 
 
2.1.9.1  4-(2-Amino-3-cyano-4-phenyl-1H-pyrrol-1-yl)-N-(4-
sulfamoyl-phenyl)benzamide14                                                                                            
Brown powder, yield 74%, melting point 220 °C, IR:  νmax./cm
-1
 
3342.64-3259.70 (NH, 2NH2), 3070.68 (CH arom.), 2204.64 
(CN), 1658.78 (C=O), 1321.24, 1157.29 (SO2). 
1
H NMR 
(DMSO-d6) δ: 7.09-8.15 (m, 18H, Ar-H + CH pyrrole + NH2, 
D2O exchangeable+ SO2NH2, D2O exchangeable), 10.71 (s, 
1H, NH, D2O exchangeable). Anal. Calcd. for C24H19N5O3S 
(457.51): C, 63.01;  H, 4.19; N, 15.31. Found: C, 63.19; H, 
4.23; N, 15.47. Ms (m/z, %): 457 (M
+
, 2.59).                          
 
2.1.9.2.  4-(2-Amino-3-cyano-4-phenyl-1H-pyrrol-1-yl)-N-(4-
(N-(5-methylisoxazol-3-yl)sulfamoyl)phenyl)benzamide15 
Brown powder, yield 63%, melting point 220 °C, IR:  νmax./cm
-1
 
3346.50-3209.55 (2NH, NH2), 3068.75 (CH arom.), 2204.64 
(CN), 1726.29 (C=O), 1319.31, 1165 (SO2). 
1
H NMR (DMSO-
d6) δ: 2.30 (s, 3H, CH3), 6.13 (s, 1H, CH oxazole), 7.08-8.09 
(m, 16H, Ar-H + CH pyrrole + NH2, D2O exchangeable), 10.73 
(s, 1H, NH amide, D2O exchangeable), 11.32 (s, H, SO2NH, 
D2O exchangeable). Anal. Calcd. for C28H22N6O4S (538.58): C, 
62.44;  H, 4.12; N, 15.60. Found: C, 62.57; H, 4.23; N, 15.84.                                                                       
 
2.1.10. Synthesis of compounds 16,17                                                                      
A solution of 14, 15 (4.58 g, 5.39 g respectively, 0.01 mol.) in 
formic acid (30 ml) was refluxed for 10 hours. The reaction 
mixture was cooled, poured on ice/water and the yielded solid 
was crystallized from methanol to give 16, 17 respectively                                                                                       
 
2.1.10.1.   4-(4-Oxo-5-phenyl-3,4-dihydro-7H-pyrrolo[2,3-
d]pyrimidin-7-yl)-N-(4-sulfamoylphenyl)benzamide16      
Brown powder, yield 38%, melting point 240 °C, IR:  νmax./cm
-1
 
3334.92-3261.63 (2NH, NH2), 3064.89 (CH arom.), 2954.95 
(CH aliph.),1668.43, 1651.07 (2C=O), 1319.31, 1157.29 (SO2). 
1
H NMR (DMSO-d6) δ: 7.08-8.14 (m, 17H, Ar-H + CH pyrrole 
+ NH, D2O exchangeable + SO2NH2, D2O exchangeable), 8.36 
(s, 1H, CH pyrimidine), 10.70 (s, 1H, NH, D2O exchangeable). 
Anal. Calcd. for C25H19N5O4S (485.52): C, 61.85;  H, 3.94; N, 
14.42. Found: C, 62.02; H, 3.97; N, 14.60. Ms (m/z, %): 485 
(M
+
, 5.19).                    
2.1.10.2.  N-(4-(N-(5-methylisoxazol-3-yl)sulfamoyl)phenyl)-
4-(4-oxo-5-phenyl-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-
yl)benzamide17                   
Brown powder, yield 47.5%, melting point 265 °C, IR:  
νmax./cm
-1
 3317.56-3246.20 (3NH), 3066.82 (CH arom.), 
2954.95 (CH aliph.), 1670.35 (2C=O), 1319.31, 1165 (SO2). 
1
H 
NMR (DMSO-d6) δ: 2.30 (s, 3H, CH3), 6.14 (s, 1H, CH 
oxazole), 7.32-8.12 (m, 15H, Ar-H + CH pyrrole + NH, D2O 
exchangeable), 8.35 (s, 1H, CH pyrimidine), 10.63 (s, 1H, NH 
amide, D2O exchangeable), 11.36 (s, H, SO2NH, D2O 
exchangeable). Anal. Calcd. for C29H22N6O5S (566.59): C, 
61.48;  H, 3.91; N, 14.83. Found: C, 61.62; H, 3.97; N, 14.98.                                                                           
 
2.1.11. Synthesis of compounds 18-24                                                                         
A mixture of 2 (3.03 g, 0.01 mol.) with the corresponding 
aromatic benzoyl chloride or sulfonyl chloride (0.01 mol) in 
dry benzene (30 ml) ,add 4 drops pyridine was refluxed for 6 
hours.The reaction mixture was concentrated and cooled.The 
yielded solid was crystallized from ethanol to give 18-24, 
respectively.   
                                                                                           
2.1.11.1. 4-(2-Benzamido-3-cyano-4-phenyl-1H-pyrrol-1-yl) 
benzoic acid 18  
Green powder, yield 44.6%, melting point 240 °C, IR:  
νmax./cm
-1
 3336.85 (NH), 3062.96 (CH arom.), 2534.46 (OH), 
2202.71 (CN), 1724.36, 1693.50 (2 C=O). 
1
H NMR (DMSO-
d6) δ: 6.05 (s, 1H, NH, D2O exchangeable), 6.96-8.13 (m, 15H, 
Ar-H + CH pyrrole), 13.10 (s, 1H, OH, D2O exchangeable). 
Anal. Calcd. for C25H17N3O3 (407.42): C, 73.70;  H, 4.21; N, 
10.31. Found: C, 73.88; H, 4.26; N, 10.47. 
 
2.1.11.2.  4-(2-(4-Chlorobenzamido)-3-cyano-4-phenyl-1H-
pyrrol-1-yl)benzoicacid19 
Green powder, yield 55%, melting point 190 °C, IR:  νmax./cm
-1
 
3352.28 (NH), 3055.24 (CH arom.), 2553.75 (OH), 2202.71 
(CN), 1693.50 (2 C=O). 
1
H NMR (DMSO-d6) δ: 6.05 (s, 1H, 
NH, D2O exchangeable), 6.76-8.28 (m, 14H, Ar-H + CH 
pyrrole), 13.10 (s, 1H, OH, D2O exchangeable). 
13
C NMR 
(DMSO-d6) δ: 71.3, 113.5 (C≡N), 118.0, 123.1, 125.5, 125.9 
(2), 127.0, 129.1 (2), 130.0 (2), 131.0 (2), 131.5 (2), 133.6 (2), 
134.7, 138.2 (2), 141.1, 148.8, 166.9 (CONH), 167.1 (COOH). 
Anal. Calcd. for C25H16ClN3O3 (441.87): C, 67.96;  H, 3.65; N, 
9.51. Found: C, 68.09; H, 3.69; N, 9.62.  
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2.1.11.3. 4-(3-Cyano-2-(4-nitrobenzamido)-4-phenyl-1H-
pyrrol-1-yl)benzoicacid 20 
Green powder, yield 32%, melting point 210 °C, IR:  νmax./cm
-1
 
3336.85 (NH), 3062.96 (CH arom.), 2534.46 (OH), 2202.71 
(CN), 1724.36, 1693.50 (2 C=O).   
1
H NMR (DMSO-d6) δ: 
6.05 (s, 1H, NH, D2O exchangeable), 6.75-8.31 (m, 14H, Ar-H 
+ CH pyrrole), 13.10 (s, 1H, OH, D2O exchangeable).                                
Anal. Calcd. for C25H16N4O5 (452.43): C, 66.37;  H, 3.56; N, 
12.38. Found: C, 66.61; H, 3.60; N, 12.53.                                                                        
 
2.1.11.4.  4-(3-Cyano-2-(2,4-dichlorobenzamido)-4-phenyl-1H-
pyrrol-1-yl)benzoicacid21                                                                                                  
Green powder, yield 38.2%, melting point 178-180 °C, IR:  
νmax./cm
-1
 3336.85 (NH), 3066.82 (CH arom.), 2534.46 (OH), 
2202.71 (CN), 1724.36, 1697.36 (2 C=O). 
1
H NMR (DMSO-
d6) δ: 6.05 (s, 1H, NH, D2O exchangeable), 6.75-8.28 (m, 13H, 
Ar-H + CH pyrrole), 13.00 (s, 1H, OH, D2O exchangeable).                         
Anal. Calculated. for C25H15Cl2N3O3 (476.31): C, 63.04;  H, 
3.17; N, 8.82. Found: C, 63.17; H, 3.25; N, 8.9. 
 
2.1.11.5.  4-(3-Cyano-4-phenyl-2-(phenylsulfonamido)-1H-
pyrrol-1-yl)benzoicacid22                                                                                                                        
Green powder, yield 41%, melting point 114 °C, IR:  νmax./cm
-1
 
3336.85 (NH), 3062.96 (CH arom.), 2538.32 (OH), 2202.71 
(CN), 1693.50 (C=O), 1300.02, 1149.57 (SO2). 
1
H NMR 
(DMSO-d6) δ: 6.06 (s, 1H, NH, D2O exchangeable), 6.82-8.22 
(m, 15H, Ar-H + CH pyrrole), 13.10 (s, 1H, OH, D2O 
exchangeable). Anal. Calcd. for C24H17N3O4S(443.47): C, 
65.00;  H, 3.86; N, 9.48. Found: C, 65.17; H, 3.92; N, 9.62.                                                                              
 
2.1.11.6.  4-(2-(4-Chlorophenylsulfonamido)-3-cyano-4-
phenyl-1H-pyrrol-1-yl)benzoicacid 23 
Green powder, yield 44%, melting point 135 °C, IR:  νmax./cm
-1
 
3340.71 (NH), 3093.98 (CH arom.), 2538.32 (OH), 2202.71 
(CN),1693.50 (C=O), 1327.03,1157.29 (SO2). 
1
H NMR 
(DMSO-d6) δ: 6.05 (s, 1H, NH, D2O exchangeable), 6.75-8.13 
(m, 14H, Ar-H + CH pyrrole), 13.06 (s, 1H, OH, D2O 
exchangeable). 
13
C NMR (DMSO-d6) δ: 71.4, 113.5 (C≡N), 
118.3, 123.1, 125.2, 125.9 (2), 127.0, 129.1 (2), 129.9 (4), 
130.5 (2), 131.2 (2), 133.6, 139.5, 139.9 (2), 148.8, 167.1 
(COOH). Anal. Calcd. for C24H16ClN3O4S(477.92): C, 60.32;  
H, 3.37; N, 8.79. Found: C, 60.49; H, 3.41; N, 8.96. Ms (m/z, 
%): 477 (M
+
, 0.71), 479 (M
+2
, 0.38) 
 
2.1.11.7. 4-(3-Cyano-2-(4-methylphenylsulfonamido)-4-
phenyl-1H-pyrrol-1-yl)benzoicacid24    
Green powder, yield 53%, melting point 220 °C, IR:  νmax./cm
-1
 
3317.56 (NH), 3062.96 (CH arom.), 2542.18 (OH), 2202.71 
(CN), 1689.64 (C=O), 1384.89, 1153.43 (SO2). 
1
H NMR 
(DMSO-d6) δ: 2.36 (s, 3H, CH3), 6.05 (s, 1H, NH, D2O 
exchangeable), 6.76-8.13 (m, 14H, Ar-H + CH pyrrole), 13.10 
(s, 1H, OH, D2O exchangeable). Anal. Calcd. for 
C25H19N3O4S(457.50): C, 65.63;  H, 4.19; N, 9.18. Found: C, 
65.81; H, 4.23; N, 9.31.    
 
2.2. Biological evaluation 
2.2.1. In vitro cytotoxicity assay                         
Newly synthesized compounds 2-24 were subjected to in vitro 
cytotoxicity evaluation against both human liver HepG2 and 
human breast MCF-7 cancer cell lines. The anticancer 
screening was carried out at the Regional Center for Mycology 
& Biotechnology, Al-Azhar University, Cairo, Egypt using 
doxorubicin as reference standard following the previously 
reported MTT assay method [20]  
 
2.2.1.1. MTT proliferation assay 
The tested human carcinoma cell lines were obtained from the 
American Type Culture Collection (ATCC, Rockville, MD). 
The cells were grown on RPMI-1640 medium supplemented 
with 10% heat inactivated fetal calf serum, 1% L-
glutamine and 50µg/ml gentamycin. The cells were maintained 
at 37ºC in a humidified atmosphere with 5% CO2 incubator 
(Shellab 2406, USA) and were subcultured 2-3 times a week.                                                                                       
 
For antitumor assays, the tumor cell lines were suspended in 
medium at concentration 5x10
4 
cell/well in Corning
®
 96-well 
tissue culture plates and then incubated for 24 hours. Then the 
tested compounds were added into 96-well plates (six 
replicates) to achieve seven concentrations for each compound. 
Six vehicle controls with media or 0.5 % DMSO were running 
for each of the 96 well plate as a control.  
 
After incubating for 24 hours, the numbers of viable cells were 
determined by the MTT test. Briefly, the media was removed 
from the 96 well plate and replaced with 100 µl fresh culture 
RPMI 1640 medium without phenol red then 10 µl of the 12 
mM MTT (Sigma) stock solution (5 mg of MTT in 1 mL of 
PBS) to each well including the untreated controls. The 96 well 
plates were then incubated at 37°C and 5% CO2 for 4 hours.  
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An 85 µl aliquot of the media was removed from the wells and 
50 µl of DMSO was added to each well and mixed thoroughly 
with the pipette and incubated at 37°C for 10 minutes. Then, 
the optical density was measured at 590 nm with the microplate 
reader (SunRise, TECAN, Inc, USA) to determine the number 
of viable cells.                    
                       
2.2.1.2 VEGFR-2 inhibition in human liver cancer cell line 
HepG-2                                 
In a trial to explore the mechanism of action of the most active 
compounds 5,9,12 and 13, they were subjected to in vitro 
evaluation of their VEGFR-2 inhibition activity on HepG2 cell 
line using the human VEGFR2/KDR ELISA kit and percentage 
inhibition was calculated and compared with that of 
doxorubicin. It was carried out at VACSERA, Cairo, Egypt.                                                                 
Cell Line HepG2 was obtained from American Type Culture 
Collection. HepG2 cells were cultured using Dulbecco's 
Modified Eagle's medium (DMEM), supplemented with 10% 
fetal bovine serum (FBS), 10 μg/ml of insulin and 1% 
penicillin-streptomycin.  
 
The cells (cells density 1.2 –1.8 ×10,000 cells/well) were 
cultured in a volume of 100µl complete growth medium, 
treated with100 μlof IC50 value of the tested compounds or the 
standard reference drug per well in 96-well plate and incubated 
for 24 hours. The cells were harvested and homogenates were 
prepared in saline using a tight pestle homogenizer until 
complete cell distribution [21].The kit used a double-antibody 
sandwich enzyme-linked immunosorbent assay (ELISA) to 
assay the level of human VEGFR-2 in samples. An anti-human 
VEGFR2/KDR coating antibody is adsorbed onmicrowells. 
Human VEGFR2/KDR present in the sample or standard bound 
to antibodies adsorbed to the microwells.  
 
A biotin-conjugated anti-human VEGFR2/KDR antibody was 
added and bound to human VEGFR2/KDR captured by the first 
antibody. Following incubation unbound biotin-conjugated 
anti-human VEGF-R2/KDR antibody was removed during a 
wash step. Streptavidin-HRP was added and bound to the 
biotin-conjugated anti-human VEGFR2/KDR antibody. Then 
unbound Streptavidin-HRP was removed during a wash step 
and tetramethyl-benzidine (TMB) substrate solution reactive 
with HRP was added to the wells. A coloured product was 
formed in proportion to the amount of human VEGFR2/KDR 
present in the sample or standard. The reaction was terminated 
by addition of acid and absorbance was measured at 450 nm. A 
standard curve was prepared from 7 human VEGFR2/KDR 
standard dilutions and then human VEGFR2/KDR level in 
sample was calculated (pg/ml).  
                                                                                 
2.2.2. Molecular docking                                                                                         
The docking process includes the prediction of ligand 
conformation and orientation within a targeted binding site, and 
the possible ligand-protein interactions. In general, docking 
aims at accurate structural modeling of the new hits and correct 
prediction of the activity [22] .The most active four compounds 
5, 9, 12 and 13 were subjected to the molecular docking to 
reveal the inhibition type of them. To perform accurate 
validation of the docking protocol, docking of the co-
crystallized ligand [sunitinib (type I inhibitor) (PDB: 4AGD), 
sorafenib (type II inhibitor) (PDB: 4ASD) or the co-crystallized 
ligand 99 (type III inhibitor) (PDB: 3VHK) should be carried 
out to study the scoring energy (S), root mean standard 
deviation (rmsd) and amino acid interactions.   All docking 
procedures were achieved by MOE (Molecular Operating 
Environment) software 10.2008 provided by chemical 
computing group, Canada.  Docking was performed using 
London dG force and refinement of the results was done using 
force field energy. The docking indicates that sunitinb is fitted 
in the active site pocket with S= -27.4945 Kcal/mol and rsmd= 
1.4790, sorafenib is fitted in the active site pocket with S= -
31.0703 Kcal/mol and rsmd= 0.7244. Docking of the most 
active compounds  5, 9, 12 and 13 in the active site of (PDB: 
4AGD) and (PDB: 4ASD) did not succeed to show fitting in 
the active site and considered as failure of the compounds to 
interact with these active sites. 
 
On the other hand, the ligand 99 is fitted in the active site 
pocket with S= -12.4340 Kcal/mol and rsmd= 0.9272. The 
same amino acid interactions were recognized with the 
hydrogen bonds previously mentioned. In this case the four 
compounds showed good fitting with a comparable manner to 
the co-crystallized ligand. 
 
RESULTS & DISCUSSIONS  
3.1. Chemistry 
Reaction of 4-substituted amino benzoic acid 1 [19,23-24] with 
malononitrile in refluxing ethanolic sodium ethoxide solution 
afforded 4-(2-amino-3-cyano-4-phenyl-1H-pyrrol-1-yl)benzoic 
acid 2 [23-25].  
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Scheme1 Reactions of compound 2 with formamide and formic 
acide afforded the derivatives 3, 4 respectively [25-29]. 
 
Scheme 2 The structure of compound 3 was confirmed by 
1
H 
NMR spectrum spectral data showed two singlet signals at 7.83 
and 8.26 ppm for 2 CH of pyrrole and pyrimidine rings, 
respectively and a singlet signal at 6.23 ppm for NH2 group 
disappeared upon deuteriation. 
1
H NMR spectral data of 
compound 4 showed a singlet signal at 12.22 ppm attributed to 
the pyrimidine NH proton disappeared upon deuteration and 
singlet signal at 8.06 ppm assigned for CH proton of the 
pyrimidine ring. 
13
C NMR spectrum showed presence of two 
signals at 163.5, 167.2 ppm for two C=O groups and COOH, 
respectively. Fusion of 2 with urea at 220°C created the oxo-
pyrrolopyrimidine derivative 5 [2,27], while reaction of 2 with 
urea in ethanol in presence of sodium hydroxide gave the 
ureido-pyrrole derivative 8 [10, 30].  
 
Scheme 2 
1
H NMR spectrum of compound 5 showed two 
singlet signals at 5.37 and 8.04 ppm for NH2 and NH groups, 
respectively, which were exchangeable upon deuteration. 
13
C 
NMR spectrum showed the presence of two signals at 155.9, 
167.6 ppm for two carbonyl groups C=O and COOH, 
respectively. On the other hand, IR spectrum of compound 8 
showed the appearance of the band corresponding to cyano 
group at 2200.78 cm
-1
. 
1
H NMR spectrum showed a singlet 
signal at 6.01 ppm for NH2 group disappeared upon deuteration 
and a singlet signal at 6.95 for CH of pyrrole. Refluxing2 with 
acetic anhydride for 15 minutes afforded the monoacetyle 
derivative 6, while continue refluxing for 3 hours, 
diacetylationtookplace, compound 7 [25, 30].  
 
Scheme 2 Compound 6 
1
H NMR spectrum displayed sharp 
singlet signal at 1.97 ppm representing the three protons of the 
CH3 group, in addition to a broad singlet at 10.17 ppm 
attributed to NH group, which disappeared upon deuterium 
exchange. 
13
C NMR spectrum revealed a signal at 25.8 ppm for 
CH3 group IR spectrum of compound 7 showed the appearance 
of three bands at 1811.16, 1745.58 and 1705.07cm
-1
 
corresponding to the three carbonyl groups 2C=O and COOH, 
respectively. 
1
H NMR spectrum showed two singlet signals at 
1.90 and 2.25 ppm for 2CH3 group. Someschiff’s bases 9-13 
prepared by refluxing different substituted aromatic aldehydes 
with 2 in absolute ethanol [31-33].  
Scheme 3 IR spectra of compounds 9-13 revealed the 
appearance of cyano group bands at 2231.64 - 2202.71 cm
-1
. 
1
H 
NMR spectra revealed the azomethine proton as sharp singlet 
signal at 8.88 - 9.14 ppm, with the disappearance of the amino 
protons singlet signal.The 2-amino-3-cyano-pyrrole derivative 
2 was treated with thionyl chloride [35-36] to produce acid 
chloride intermediate which was immediately reacted with 
sulfanilamide or sulfamethoxazole in dry benzene, in the 
presence of few drops of pyridine [2,29,31] to produce the 
corresponding amide derivatives 14 and 15, refluxing of the 
later compounds with formic acid yielded the corresponding 
pyrrolo[2,3-d]pyrimidine derivatives 16 and 17 [26-29, 36-37].  
 
Scheme 4 IR spectra of 14 and 15 showed appearance of bands 
at 3346.50-3209.55 cm
-1
 for NH and NH2 groups in addition to 
two bands at 1321.24, 1319.31 cm
-1 
and 1157.29, 1165 cm
-1
 
assignable for the SO2 group. 
1
H NMR spectra revealed 
theappearance of singlet signals attributed to the amino protons 
of the sulfonamide moiety at 7.96 and 11.32 ppm, respectively, 
which were exchangeable upon deuteration. On the other hand, 
The IR spectra of 16 and 17 revealed two bands at 1670.35-
1651.07 cm
-1
 attributed to the two carbonyl groups andat 
2204.64 cm
-1 
for the nitrile group. 
1
H NMR spectra exhibited 
the appearance of a singlet signal at 8.36 and 8.35, for CH 
proton of the pyrimidine ring.  Refluxing 2 with different 
aromatic benzoyl chloride or sulfonyl chloride in dry benzene 
and few drops of pyridine afforded the benzamido- 18-21 and 
phenylsulfonamido-pyrrole derivatives 22-24 [2, 28, 30]  
 
Scheme 5 IR spectra revealed two bands attributed to the two 
carbonyl groups at 1724.63- 1693.50 cm
-1
 for compounds 18-
21and the appearance of SO2 bands at 1384.89-1300.02 cm
-1 
and 1157.29-1149.57 cm
-1
 for compounds 22-24. 
13
C NMR 
spectrum of compound 19 revealed two signals at 166.9 and 
167.1 ppm for the two carbonyl groups of CONH and COOH, 
respectively, while compound 23 spectrum showed only one 
signal at 167.1 ppm for COOH. 
 
3.2. Biological evaluation                                                                                              
3.2.1. In vitro cytotoxicity assay 
All the newly synthesized compounds 2-24 were evaluated for 
their cytotoxic activity against human breastMCF-7andhuman 
liver HepG2 cancer cell lines using doxorubicin as reference 
standard following the previously reported MTT assay method 
[20].       
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I: Imatinib, II: Vandetanib, III: Sunitinib, IV: Gefitinib, V: Eroltinib, VI: Lapatinib 
Figure 1: some pyrrole and pyrimidine derivatives have anticancer activity 
Scheme:1.  Synthetic pathways of the key intermediate 2 
 
Reagents and conditions: a) Phenacyl bromide, abs. ethanol, Reflux 3h; 
b) Sodium ethoxide/ malononitrile, abs. ethanol, reflux 12h 
Scheme: 2 Synthetic pathways of the compounds 3-8   
 
Reagents and conditions: a) formamide, reflux10h; b)formic acid, reflux10h; c) urea, fused at 15min. 
 d) acetic anhydride, reflux 13min; e) acetic anhydride, reflux 3h; f) urea/sodium hydroxide, reflux12h 
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Scheme: 3 General synthetic pathway of the compounds 9-13  
 
Reagents and conditions: a) aromatic aldehydes, abs. ethanol, reflux 6h 
Scheme: 4 General synthetic pathways of the compounds 14-17 
 
Reagents and conditions: a) thionyl chloride, reflux 3h; b) sulfonamides, pyridine,benzene, reflux 6-8h; c) formic acid, reflux10h 
 
Reagents and conditions: a) aryl benzoyl chloride,benzene, reflux 6h; b) aryl sulfonyl chloride,benzene, reflux 6h 
 
The results are mean of three separated experiments ±S.E. 
Table 1 Pyrrolederivatives 6-15 and 18-24; The acetyl 
substituent of the amino pyrrole6 and 7, respectively, showed a 
good activity against HepG2 with approximately the same IC50 
values (3.85±0.30 and   3.81±0.3μM, respectively). On the 
other hand, the ureido derivative 8 was the least active one 
(IC50 = 13.59±1.2μM). These compounds were inactive against 
human breastMCF-7(IC50˃50μm). Regarding the effect of 
substituent on schiff’s base, the unsubstituted derivative 9 and 
the vanillin derivative 13 had a good activity against HepG2 
(IC50 = 1.87±0.12μM). While the p-N, N-dimethyl derivative 
12 showed nearly the same activity(IC50 = 1.78±0.10μM). On 
the other hand, the p-methoxysubstituent11 had a moderate 
activity (IC50 = 4.79±0.3μM), while the p-chlorosubstituent10 
had the least activity against HepG2 (IC50 = 12.51±1.1μM).                                                             
Although the activity of these compounds against MCF-7 was 
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very weak, by comparing their activity, compounds 12 and 13 
were the most active ones (IC50 = 19.25±0.47 and 
23.12±1.25μM, respectively).  
Table 1: IC50 of the newly synthesized compounds against 
HepG2 and MCF-7 
compound 
HepG2 
IC50±S.E.( μM ) 
MCF-7 
IC50±S.E.( μM ) 
2 40.7±8.3 49.21.8 
3 3.29±0.25 >50 
4 3.38±0.28 >50 
5 1.91±0.10 >50 
6 3.85±0.30 >50 
7 3.81±0.35 >50 
8 13.59±1.2 >50 
9 1.87±0.13 40.89±1.5 
10 12.51±1.1 >50 
11 4.79±0.3 >50 
12 1.78±0.10 19.25±0.47 
13 1.87±0.12 23.12±1.25 
14 >50 >50 
15 >50 >50 
16 >50 >50 
17 >50 >50 
18 41.2±1.4 19.2±0.5 
19 >50 >50 
20 >50 >50 
21 >50 >50 
22 9.13±0.2 40.2±1.4 
23 >50 >50 
24 7.35±0.2 >50 
Doxorubicin 1.13±0.10 1.49±0.023 
IC50 was obtained from three separated experiments ± S.E. 
 
On the other hand, compound 9 was less active (IC50 = 
40.89±1.5μM) and compounds 10 and 11were inactive 
(IC50˃50 μM). In this series, compound 12 was considered the 
most active one against both HepG2 and MCF-7 cell lines.                                                          
Converting the carboxylic moiety into the corresponding amide 
derivatives using sulfanilamide 14 and sulfamethoxazole15 led 
to inactive derivatives (IC50˃50 μM) against both HepG2 and 
MCF-7. Within phenylsulfonamido series 22-24, the p-methyl 
phenylsulfonamide derivative 24 was the most active 
compound against HepG2 (IC50 = 7.35±0.2 μM), while the 
unsubstituted analogue 22 showed a moderate activity (IC50 = 
9.13±0.2 μM). On the other hand, the p-chloro derivative 23 
was inactive (IC50 ˃50 μM).  
Table 2: VEGFR 2 percentage inhibition  
Compound  VEGFR 2 residual conc. VEGFR-2 % inhibition 
5 686.491 85.3 
9 740.914 84.1 
12 775.862 83.4 
13 590.541 87.3 
Doxorubicin 978.443 79.0 
 
In case of benzamido derivatives 18-21, all compounds were 
inactive (IC50 ˃50 μM) except the unsubstituted derivative 18 
which had a weak activity (IC50 = 41.2±1.4 μM). All the 
compounds 18-24 were inactive against MCF-7 (IC50 ˃50 μM) 
except for 18 and 22 which exhibited a moderate to weak 
activity (IC50 = 19.2±0.5 and 40.2±1.4 μM, respectively).                                                                      
Pyrrolopyrimidine derivatives 3-5 and 16,17; The 4-amino, 2-
oxo-pyrrolopyrimidine derivative5 was the most active 
compound in this series against HepG2 (IC50 = 1.91±0.10μM), 
while both the 4-amino derivative 3 and the 4-oxo derivative 4 
showed lower activity (IC50 = 3.29±0.25 and 3.38±0.28μM, 
respectively). On the other hand, these compounds were 
inactive against MCF-7 cell line (IC50 ˃50 μM). The 
sulfonamide pyrrolopyrimdine derivatives 16 and 17 were 
inactive (IC50˃50 μM) against both HepG2 and MCF-7. 
   
3.2.2 VEGFR-2 inhibition in human liver cancer cell line 
HepG-2                          
In a trial to explore the mechanism of action of the most active 
compounds 5, 9, 12 and 13, they were subjected to in vitro 
evaluation of their VEGFR-2 inhibition activity on HepG2 cell 
line using the human VEGFR2/KDR ELISA kit and percentage 
inhibition was calculated and compared with that of 
doxorubicin. It was carried out at VACSERA, Cairo, Egypt. 
The inhibition results for the tested compounds are displayed in 
Table 2. 
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In vitro biological evaluation of compounds 5, 9, 12 and 13 as 
VEGFR-2 inhibitors revealed remarkable inhibition activity in 
the range of 83.4 to 87.3% compared to doxorubicin which was 
active as inhibitor by 79.0%.  Compound 13 exhibited the most 
promising activity as VEGFR-2 inhibitor with inhibition 
percentage of 87.3%. 
IC50 value of the most active compound 13 was determined in 
order to compare its biological activity with known marketed 
VEGFR-2 inhibitors using the human VEGFR2/KDR ELISA 
kit. Five serial dilutions were prepared and measured to 
construct a standard curve. From linear regression equation, 
IC50 value could be calculated .It was found that IC50 value of 
VEGFER-2 inhibition of compound 13 was 0.13μM; Fig (2).                                                                                           
Many VEGFR-2 inhibitors were approved by FDA to be used 
for cancer treatment as VandetanibII with IC50 values of 
0.4±0.13 μM [38].   
 
Figure 2: Standard curve of compound 13 
 
3.3. Molecular modeling and docking results                                                         
The docking process includes the prediction of ligand 
conformation and orientation within a targeted binding site, in 
addition to the possible ligand-protein interactions. In general, 
docking aims at accurate structural modeling of the new hits 
and correct prediction of the activity [22].Vascular endothelial 
growth factor receptors (VEGFRs) classified into: VEGFR-
1(Flt-1), VEGFR-2 (KDR/Flk-1) and VEGFR-3(Flt-4) [39]. 
Downstream effects of VEGFR-2 activation in the vascular 
endotheliuminclude cell proliferation, migration, permeability 
and survival, resulting in vasculogenesisand angiogenesis 
[12].So VEGFR-2 inhibitors are very important anticancer 
agents.                                                                                                                       
The accurate validation of the docking of the co-crystallized 
ligand [sunitinib (type I inhibitor) (PDB: 4AGD), sorafenib 
(type II inhibitor) (PDB: 4ASD) or the co-crystallized ligand 
99 (type III inhibitor) (PDB: 3VHK)] should be carried out. 
Fig. 3, 4, 5. All docking procedures were attained by MOE 
(Molecular Operating Environment) software 10.2008 provided 
by chemical computing group, Canada. Performing molecular 
docking using  (PDB: 4AGD), in which we were testing the 
ability of the compounds to inhibit VEGFR-2 in its ATP 
binding site did not succeed as the docking score indicates 
failure of our compounds to interact with this site.  
 
Figure: 3 Docking of the co-crystallized ligand [Sunitinib 
(Type I inhibitor)] 
 
Figure 4: Docking of the co-crystallized ligand [Sorafenib 
(Type II inhibitor)] 
 
Figure: 5 Docking of the co-crystallized ligand [Ligand 99 
(Type III inhibitor)] 
 
Table: 3 Molecular docking scores  
compound (S) Kcal/ mol 
5 -12.1220 
9 -12.8774 
12 -12.8541 
13 -13.6740 
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(a)   (b) 
Figure: 6 2D interactions of active compound 13                    
(a) with the allosteric binding site  (b) as type II inhibitor 
 
(a)         (b)         (c) 
Figure: 7 2D interactions of active compounds with allosteric 
binding site (a) compound 5 (b) compound 9 (c) compound 12  
The same case was there in our trial to dock the compounds in 
(PDB: 4ASD) in which type II inhibitor was co-crystallized 
with VEGFR-2. However, in case of type III inhibitor with 
PDB ID: 3VHK in a comparable manner to co-crystallized 
ligand. Ligand 99 (the co-crystallized ligand) was fit on the 
active site of VEGFR-2 with S= -12.4340 Kcal/mol and rsmd= 
0.9272. The molecular docking scores of the most active four 
compounds are shown in Table 3. From the table, it could be 
realized that, all compounds showed a good energy score 
compared with that of the co-crystallized ligand, especially 
compound 13 with the least energy score. Compound 13 
interacts with the allosteric binding site through hydrogen 
bonding interaction with Asp 1046, areniumcation interactions 
with Lys 868 and Arg1027. Also, the high affinity of the 
compound to the allosteric pocket is attributed to the 
hydrophobic interactions between the compound and the 
hydrophobic side chain of amino acids Leu 1019, Ile 1025, Ile 
892, Ile 888 and Ile 1044 which line the allosteric pocket. Fig 
(6 a,b). Also, compounds 5, 9 and 12 revealed almost the same 
pattern of interaction with the allosteric binding site. They form 
hydrogen bonding interaction with Asp 1046 in addition to 
areniumcation interaction with Lys 868 and the hydrophobic 
interactions Fig (7 a,b,c) 
 
CONCLUSION 
From the observed data, it has been noticed that, all the tested 
compounds reflected promising activity against HepG2 cell 
line and mild or no activity at all against MCF-7 except 
compound 18 which revealed moderate activity against MCF-7 
(IC50 = 19.2±0.5 μM) but it showed weak activity against 
HepG2 (IC50 = 41.2±1.4 μM). Structure-activity relationship 
based on the above results indicated that, substituting the amino 
pyrrole with mono- and di-acetyl moiety in compounds 6 and 7 
with approximately the same IC50 values (3.85±0.30 and 
3.81±0.35μM, respectively) appears more favorable for 
constructing antitumor compounds than the substitution with 
ureido moiety in compound 8 (IC50 = 13.59±1.2μM). Moreover, 
aryl group substitution on schiff’s base played a controlling 
role in developing the exhibited pharmacological properties. 
Substitution with an electron donating group such as 
dimethylamino 12, (IC50 = 1.78±0.10μM), seems more 
favorable than the case of an electron withdrawing substituent 
as a chlorine atom 10, (IC50 = 12.51±1.1μM). In addition, 
comparing the activity of the compounds bearing the electron 
donating groups 11 and 12, it was observed that, the activity 
increases by increasing the electron donating character of the 
substitution 11, (IC50=  4.79±0.3μM) and 12, (IC50 = 
1.78±0.10μM). However, the same results were observed in 
benzamido and phenylsulfonamido series. Compound 24, 
bearing electron donating group, has a great activity against 
HepG2 (IC50 = 7.35±0.2 μM). While the free carboxylic moiety 
was converted into amide using sulfonamides in compounds 
14-17, led to abolish the activity against both cell lines. 
Cyclization to pyrrolopyrimidine derivatives led to good 
activity especially for the 4-amino, 2-oxo-pyrrolopyrimidine 
derivative 5 which was the most active compound among this 
series. However, biological evaluation of compounds 5, 9, 12 
and 13 as VEGFR-2 inhibitors revealed remarkable inhibition 
activity in the range of 83.4 to 87.3%. Comparing IC50 value as 
VEGFR-2 inhibitor of compound 13 with vandetanib revealed 
that compound 13 was approximately 4-folds more potent than 
vandetanib. Accordingly, compound 13 may be a promising 
VEGFR-2 inhibitor anticancer agent. In the cytotoxic assay, 
most active compounds 5,9,12,13 were docked on the active 
site of VEGFR-2. They tend to be powerful inhibitors through 
acting as type III Inhibitors. They bind exclusively to the 
allosteric pocket with good amino acid interactions comparable 
to the co-crystallized ligand. Compound 13 being the most 
active in vitro VEGFR-2 inhibition assay, shows the least 
energy score. It binds to the active site through hydrogen 
bonding interaction, areniumcation interactions and the 
hydrophobic interactions. 
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